Thailand
approves medical marijuana in New Year's 'gift'
Send a link to a friend
[December 26, 2018]
By Patpicha Tanakasempipat and Panarat Thepgumpanat
BANGKOK (Reuters) - Thailand approved
marijuana for medical use and research on Tuesday, the first
legalization of the drug in a region with some of the world's strictest
drug laws.
|
The junta-appointed parliament in Thailand, a country which until
the 1930s had a tradition of using marijuana to relieve pain and
fatigue, voted to amend the Narcotic Act of 1979 in an extra
parliamentary session handling a rush of bills before the New Year's
holidays.
"This is a New Year's gift from the National Legislative Assembly to
the government and the Thai people," said Somchai Sawangkarn,
chairman of the drafting committee, in a televised parliamentary
session.
While countries from Colombia to Canada have legalized marijuana for
medical or even recreational use, the drug remains illegal and taboo
across much of Southeast Asia, which has some of the world's
harshest punishments for drug law violations.
Marijuana traffickers can be subject to the death penalty in
Singapore, Indonesia and Malaysia.
But in Thailand, the main controversy with legalization involved
patent requests by foreign firms that could allow them to dominate
the market, making it harder for Thai patients to access medicines
and for Thai researchers to access marijuana extracts.
[to top of second column] |
"We're going to demand that the government revoke all these requests
before the law takes effect," said Panthep Puapongpan, Dean of the
Rangsit Institute of Integrative Medicine and Anti-Aging.
Some Thai advocates hope that Tuesday's approval will pave the way
for legalization for recreational use.
"This is the first baby step forward," said Chokwan Chopaka, an
activist with Highland Network, a cannabis legalization advocacy
group in Thailand.
(Writing by Patpicha Tanakasempipat; Editing by Edmund Klamann)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |